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ABSTRACT
TKI resistance remains a major impediment to successful treatment of CML. 
In this study, we investigated the emerging modes of ponatinib resistance in TKI-
naïve and dasatinib resistant BCR-ABL1+ cell lines. To investigate potential resistance 
mechanisms, ponatinib resistance was generated in BCR-ABL1+ cell-lines by long-
term exposure to increasing concentrations of ponatinib. Two cell lines with prior 
dasatinib resistance demonstrated BCR-ABL1 kinase domain (KD) mutation(s) upon 
exposure to ponatinib. In one of these cell lines the T315I mutation had emerged 
during dasatinib exposure. When further cultured with ponatinib, the T315I mutation 
level and BCR-ABL1 mRNA expression level were increased. In the other cell line, 
compound mutations G250E/E255K developed with ponatinib exposure. In contrast, 
the ponatinib resistant cell lines that had no prior exposure to other TKIs (TKI-naïve) 
did not develop BCR-ABL1 KD mutations. Rather, both of these cell lines demonstrated 
Bcr-Abl-independent resistance via Axl overexpression. Axl, a receptor tyrosine kinase, 
has previously been associated with imatinib and nilotinib resistance. Ponatinib 
sensitivity was restored following Axl inhibition or shRNA-mediated-knockdown of 
Axl, suggesting that Axl was the primary driver of resistance and a potential target 
for therapy in this setting.
INTRODUCTION
Since its clinical introduction over a decade ago, 
imatinib has revolutionized the treatment of chronic 
phase-chronic myeloid leukaemia (CP-CML). However, 
approximately 30-40% of patients fail to respond optimally 
to imatinib [1]. The best-characterized mechanism of 
secondary imatinib resistance is the development of 
mutations within the BCR-ABL1 kinase domain (KD). 
More than 100 mutations have been identified which either 
prevent or significantly disrupt the binding of imatinib to 
Bcr-Abl [2]. To overcome this, second generation tyrosine 
kinase inhibitors (TKIs) including nilotinib and dasatinib 
were developed. For many imatinib resistant patients, 
second generation TKIs are an effective salvage strategy. 
However, these TKIs are completely ineffective against 
the BCR-ABL1 T315I mutation (commonly referred 
to as the gatekeeper mutation), which accounts for 
approximately 15-20% of clinically observed BCR-ABL1 
mutations [2, 3].
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Ponatinib (Iclusig®, Ariad Pharmaceuticals, 
Cambridge, MA, USA) a third generation TKI, is a potent 
Bcr-Abl inhibitor approved in the USA and Europe for 
treatment of CML patients with resistance to other TKIs. 
The medium human peak and trough plasma levels of 
ponatinib when dosed at 45 mg once daily are 145 nM 
and 64 nM respectively [4]. Ponatinib was specifically 
designed on the basis of X-ray crystallographic analysis 
of the Abl kinase domain to target native and mutant 
isoforms of Bcr-Abl, including Bcr-AblT315I. However, 
while ponatinib is the only available TKI to target Bcr-
AblT315I, the interaction of ponatinib with T315I mutant 
Bcr-Abl is weaker than its interaction with Bcr-Ablp210 
[5, 6].
While ponatinib efficiently targets Bcr-Abl with a 
single KD mutation, multiple mutations in BCR-ABL1 
within the same clone, known as “compound mutations”, 
can occur and were found to confer ponatinib resistance 
[7]. Although only a minority of Philadelphia chromosome 
positive (Ph+) leukaemia patients harbour compound 
mutations, Zabriskie and colleagues [7] demonstrated that 
patients with 12 different compound mutations, including 
those that are T315I inclusive, are highly resistant to 
ponatinib and all other available TKIs.
In addition, a sub-optimal response to TKI therapy 
can be due to the development of other Bcr-Abl dependent 
mechanisms including reduced activity of the drug-
influx transporter organic cation transporter 1 (OCT-1) 
[8–10], increased expression of drug-efflux ATP-binding 
cassette transporters, commonly ABCB1 and ABCG2 [8, 
11–17], and/or BCR-ABL1 over-expression [16, 18–20]. 
Moreover, patients who lose response to therapy without 
harbouring BCR-ABL1 KD mutations are also observed in 
the clinic. Importantly, these patients may have adequate 
inhibition of Bcr-Abl activity [21], suggesting that Bcr-
Abl independent mechanisms of resistance may drive the 
disease in these cases. Identified Bcr-Abl independent 
resistance mechanisms include the deregulation of PI3K 
signalling, Src family kinases, JAK-STAT signalling, 
and TAM (Tyro3, Axl, and Mer) family receptor tyrosine 
kinases, particularly Axl [22–27]. While the function 
of this kinase is yet to be determined, patients who are 
imatinib resistant were shown to have higher expression 
of AXL in a study by Dufies M et al. [22].
To investigate potential resistance mechanisms, 
ponatinib resistance was generated in this study 
by exposing BCR-ABL1+ cell lines to increasing 
concentrations of ponatinib. Cell lines were either TKI-
naïve, or were previously treated with dasatinib to induce 
dasatinib resistance to mimic the clinical use of ponatinib 
in TKI-resistant/refractory CML & Ph+ALL patients, 
many of which had been on dasatinib with or without the 
T315I mutation. By characterising the resultant ponatinib 
resistant cell lines, we identified that in the setting of prior 
dasatinib exposure, Bcr-Abl dependent mechanisms cause 
ponatinib resistance. However, in the TKI-naïve setting, 
Bcr-Abl-independent modes of resistance dominate, 
and Axl presents as a key mediator of this resistance, 
suggesting Axl may be a potential therapeutic target in the 
cases of ponatinib resistance.
RESULTS
Four ponatinib resistant cell lines were generated
After long-term ponatinib culture, four ponatinib 
resistant cell lines were established (Table 1 and 
Supplementary Figure 1) and all were cross-resistant 
to imatinib, nilotinib and dasatinib. To investigate the 
ponatinib resistance, Bcr-Abl kinase sensitivity assays 
were performed (using phospho-CrkL as a surrogate 
measure of Bcr-Abl kinase activity) to determine the IC50 
of ponatinib. Increased IC50 values indicated Bcr-Abl 
dependent ponatinib resistance in the two dasatinib pre-
treated ponatinib resistant cell lines: K562 T315I-R (635 
nM compared to control line 68 nM, p<0.001, n=3) and 
K562 DOX 55D-R cells (478 nM, compared to control 
line 51 nM, p<0.001, n=3), as higher concentrations of 
TKI were required to inhibit Bcr-Abl tyrosine kinase 
activity (Table 1, Supplementary Figure 2A-2B).
However, as demonstrated in (Supplementary Figure 
2C), there was no significant difference (n=3) in the 
ponatinib IC50 of the K562-R cell line (6.6 nM) compared 
to the control cell line K562 (7.2 nM). In addition, the 
K562 DOX-R cells also demonstrated a similar ponatinib 
IC50 (11.3 nM, n=3) compared to the K562 DOX control 
(8.9 nM) (Supplementary Figure 2D). To confirm the 
resistance in these two TKI naïve ponatinib treated 
cell lines, viabilities were determined after 72 hours of 
ponatinib exposure. As shown in Supplementary Figure 
3, both K562-R and K562 DOX-R cell lines were able 
to maintain high viabilities (>75%) in 200 nM ponatinib. 
These results suggested that Bcr-Abl independent 
mechanisms were likely involved in the development of 
ponatinib resistance in these two cell lines.
Resistant cell lines demonstrated BCR-ABL1 
mRNA overexpression in the development of 
ponatinib resistance
Since overexpression of BCR-ABL1 mRNA can 
cause resistance to first and second generation TKIs [23, 
28, 29], RT-QPCR was performed to determine BCR-
ABL1 transcript number in the four ponatinib resistant cell 
lines. As expected, substantial increases in the expression 
level of BCR-ABL1 mRNA were observed during the 
development of the K562 T315I-R and K562 DOX 55D-
R cell lines. There was a significant increase in BCR-ABL1 
mRNA from 1206% (relative to %BCR) in naïve cells to 
8027% in the K562 T315I-R resistant line (n=3, P<0.001) 
(Figure 1A). Moreover, BCR-ABL1 RT-QPCR on the 
intermediate stages of resistance development (from 40 nM 
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to 90 nM) revealed an increase in mRNA expression, 
peaking at 9034% in the 90 nM ponatinib intermediate, 
K562 T315I 90 nM PON (n=3, p<0.001) (Figure 1A). 
During the development of the K562 DOX 55D-R cell 
line, a step-wise increase in BCR-ABL1 mRNA was also 
observed in the intermediate stages of resistance, from 
1069% in the ponatinib naïve control cells and peaking 
at 3947% in the 50 nM ponatinib intermediate (n=3, 
P<0.001) (Figure 1B). This overexpression, however, 
then decreased to 1818% from the 100 nM intermediate 
stage onwards. The final K562 DOX 55D-R resistant 
cells (200 nM ponatinib) demonstrated a further reduction 
in BCR-ABL1 mRNA expression (1299%), which was 
not significantly different to the ponatinib naïve control 
line K562 DOX 55D (1069%) (Figure 1B). This result 
suggests that the overexpression of BCR-ABL1 mRNA 
may only facilitate early stage ponatinib resistance, and 
that other resistance mechanisms eventually predominate.
Notably, BCR-ABL1 mRNA levels also increased 
during the development of K562-R and K562 DOX-R 
cell lines, however, the gene expression levels were 
significantly lower compared to the two ponatinib 
resistant cell lines which had developed prior resistance to 
dasatinib. As demonstrated in Figure 1C, the intermediate 
stages of the ponatinib resistance development in K562 
exhibited fluctuations in the BCR-ABL1 mRNA transcript 
level, from 487% in the K562 TKI-naïve control cells, 
peaking at 1408% in the 40 nM ponatinib culture (n=3, 
P<0.001). However, the K562-R final (200 nM ponatinib) 
resistant line did not exhibit a significantly increased 
BCR-ABL1 mRNA level compared to its K562 control. 
This result suggested that the overexpression of BCR-
ABL1 mRNA may mediate early stages of ponatinib 
resistance, but it is not the major mechanism that caused 
resistance in this cell line. Conversely, the BCR-ABL1 
mRNA expression level in the K562 DOX-R ponatinib 
resistant line increased from 266% in the control line to 
871% in the final 200 nM ponatinib culture (p=0.04, n=3) 
(Figure 1D). These results suggest that the overexpression 
of BCR-ABL1 mRNA may mediate early stage ponatinib 
resistance, however, given the expression levels of BCR-
ABL1 were much lower in the prior TKI-naïve K562-R 
and K562 DOX-R cell lines than the other two ponatinib 
resistant lines, the over-expression is unlikely to be the 
only, or the dominant, resistance mechanism.
No evidence of ABCG2 up-regulation in the 
ponatinib resistant lines, while ABCB1 was up-
regulated in the K562-R ponatinib resistant cell 
line
Since overexpression of the efflux transporters ABCB1 
and ABCG2 has been demonstrated to cause resistance to 
other TKIs [11, 16, 30, 31], the protein expression levels of 
these transporters were determined via flow cytometry in the 
ponatinib resistant cell lines. No surface expression of ABCB1 
or ABCG2 was detected in the K562 T315I-R resistant or 
K562 T315I control cell lines (Supplementary Figure 4A 
and Supplementary Figure 5A). Flow cytometry did 
not detect ABCG2 expression in either of the K562 
DOX 55D-R, K562-R or K562 DOX-R resistant 
cell lines nor in their corresponding parental controls 
(Supplementary Figure 4B-4D).
Notably, the K562 DOX 55D-R and the K562 
DOX-R resistant cell lines demonstrated no changes 
in ABCB1 expression levels compared to their 
corresponding ponatinib naïve, ABCB1-overexpressing 
control lines (Supplementary Figure 5B, 5D). These 
results suggest that the ABCB1 overexpression was not 
required for the ponatinib resistance, hence ABCB1 
overexpression is not a major cause of ponatinib 
resistance in the two cell lines.
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Interestingly, while the control line K562 did not 
express cell surface ABCB1 (Supplementary Figure 5C), 
cell surface ABCB1 expression was observed in the K562-R 
ponatinib resistant culture, however the ponatinib IC50 in this 
cell line was similar to the control line. These data suggest 
that although ABCB1 might play a role in the development 
of resistance, it is unlikely that ABCB1 overexpression alters 
the intracellular concentration of ponatinib, and therefore this 
ABCB1 overexpression is not likely to mediate the observed 
ponatinib resistance by effluxing ponatinib.
K562 T315I-R ponatinib resistant line 
demonstrated an increased BCR-ABL1T315I 
mutation level
Ponatinib is a pan-Bcr-Abl inhibitor that 
effectively inhibits Bcr-Abl harbouring any of the 
identified single kinase domain mutations, including 
T315I. Previous results [28] revealed the control 
cell line K562 T315I to have 44% T315I BCR-ABL1 
KD gatekeeper mutation, causative of resistance to 
dasatinib, cross-resistant to imatinib and nilotinib, 
but sensitive to ponatinib. Conventional (Sanger) 
sequencing was performed on the intermediate cell 
lines generated during the development of ponatinib 
resistance and revealed a slow but steady increase in 
T315I% from 44% in the control line peaking at 66% 
(Figure 1A), with a comparatively reduced ponatinib 
sensitivity. Notably, during resistance development, 
the T315I mutation was undetectable in the 10 nM 
ponatinib intermediate (limit of detection is 10%), but 
was again present (at 49%) in the 20 nM ponatinib 
intermediate cell line (n=2).
The percentage of T315I in cell lines 
corresponded to ponatinib sensitivity
Ponatinib was designed to specifically target 
BCR-ABL1T315I therefore it was necessary to confirm 
our observation that increased T315I mutation burden 
Figure 1: Increased T315I% was detected in the K562 T315I cell line during development of ponatinib resistance. 
Reduction of BCR-ABL1 mRNA overexpression coincided with the emergence of a compound mutation in the development of K562 DOX 
55D-R ponatinib resistant cell line. Overexpression of BCR-ABL1 mRNA level was observed in the intermediate cell lines, and the final 
(A) K562 T315I-R (100 nM) and (D) K562 DOX-R (200 nM) resistant cell lines, but not the (B) K562 DOX 55D-R (200 nM) and (C) 
K562-R (200 nM) resistant cell lines. (A) The percentage of T315I mutation was also increased in the K562 T315I-R (100 nM) cell line. 
(B) The reduction in the overexpression of BCR-ABL1 in 100 nM intermediate followed the emergence of the compound mutation G250E/
E255K. No mutation was detected in the (C) K562-R (200 nM) or (D) K562 DOX-R (200 nM) resistant cell lines. Error bars represent SD. 
mRNA expression represents the mean of at least three independent experiments performed in triplicate, *p<0.05, **p<0.01 and ***p<0.005 
compared to the corresponding parental control lines (CTL).
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correlated with the development of ponatinib resistance. 
We assessed the effect of the T315I mutation burden 
on ponatinib sensitivity by conducting ponatinib IC50 
analyses in an independent cell line - BCR-ABL1 negative 
HL60 transduced with either BCR-ABL1 p210 or BCR-
ABL1T315I (Figure 2 and Supplementary Figure 6A). 
HL60-BCR-ABL1T315I cells were diluted in HL60-BCR-
ABL1 p210 cells to generate a T315I serial dilution. Mean 
ponatinib IC50 values reduced gradually from 56 nM in 
the 100% BCR-ABL1T315I positive HL60 cell population, 
to 7 nM in the 10% T315I mutation dilution compared 
to 6 nM when no T315I was present in HL60-BCR-
ABL1 p210 (Figure 2). Statistically significant reductions 
were found in the cell populations with 75%, 50% and 
25% T315I compared to the preceding dilutions (p<0.01, 
p=0.04 and p=0.03 respectively, all n=3). When dasatinib 
sensitivity was similarly assessed (Supplementary Figure 
6B), incomplete kinase inhibition at even the highest 
dasatinib concentration rendered dasatinib IC50 values 
indeterminable for any percentage of T315I tested. 
These results suggest that if even a small proportion of 
a cell population was T315I-positive the mutant clone 
would result in overt resistance. In addition, although the 
sensitivity to ponatinib decreased with increasing T315I, 
both T315I-mutant cells and non-mutant cells were 
inhibited at pharmacologically relevant concentrations. 
Taken together, these dilution experiments confirm that 
the percentage of T315I in a cell population significantly 
impacts sensitivity to ponatinib treatment within clinically 
relevant ranges.
K562 DOX 55D-R ponatinib resistant line 
harboured the compound mutations G250E and 
E255K
Conventional Sanger sequencing was unable to 
detect a BCR-ABL1 KD mutation in the K562-R and 
K562 DOX-R resistant cell lines. G250E (64%) and 
E255K (55%) were present in the K562 DOX 55D-
R (200 nM) cell line, however neither the K562 DOX 
55D ponatinib naïve control cell line, nor any of the 
intermediate cell lines, harboured a mutation detectable 
by Sanger sequencing (limit of detection is 10%).
Next, samples from the resistant line and the 
earlier intermediate stages were further analysed by next 
generation sequencing termed Single Molecule Consensus 
Sequencing (SMCS) [32] to investigate whether the 
mutations had emerged at an earlier time point (sensitivity 
<1%). As demonstrated in Figure 1B, G250E/E255K 
compound mutations were detected at 14% in the 100 
nM intermediate K562 DOX 55D cell line. Interestingly, 
a single mutation E279K and a single mutation E255K 
Figure 2: Ponatinib IC50 decreased in response to gradual reductions in the percentage of the T315I mutant. Mean 
poantinib IC50 values were gradually reduced in the BCR-ABL1T315I transduced HL60 cell line following dilution of the T315I with native 
BCR-ABL1p210 transduced HL60 cells. The reductions were significant in 75% (compared to 100%, p=0.004), 50% (compared to 75%, 
p=0.04) and 25% (compared to 50%, p=0.03) T315I dilutions (all n=3). *p<0.05, data are mean + SD.
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were observed in 0.92% and 0.72% respectively in this 
100 nM intermediate cell line. In the resistant line K562 
DOX 55D-R (200 nM), the compound mutations G250E/
E255K (54%) were also confirmed by SMCS (Figure 1B) 
and there was no other mutation detected.
K562-R and K562 DOX-R ponatinib resistant 
lines demonstrated increased cell adhesion
Interestingly, the resistant cell lines K562-R and 
K562 DOX-R demonstrated increased adherence in 
culture as observed by morphology change, while the 
cells in the controls K562 and K562 DOX remained in 
suspension (Figure 3A). Due to this observation, flow 
cytometry was performed to assess the expression of the 
adhesion marker CD44 (E-selection, homing cell adhesion 
molecule or lymphocyte homing receptor) [33] in the two 
resistant cell lines and their respective controls. Increased 
adherence in K562 imatinib resistant cells (with CD44 
staining positive) was reported in a previous publication 
[33]. As indicated in Figure 3B, the K562 control line 
was negative for CD44 while very small populations in 
the control line K562 DOX were positive for the adhesion 
marker. Conversely, the staining of CD44 was strongly 
positive in the two ponatinib resistant lines. This supported 
the morphology change observed in the resistant lines, and 
given that the increased adhesion was only observed in the 
two Bcr-Abl independent resistant cell lines, suggests that 
the adherence is likely to be associated with the Bcr-Abl 
independent mechanism of ponatinib resistance.
K562-R and K562 DOX-R ponatinib resistant 
lines demonstrated Axl overexpression
Increased adherence is a hallmark of Axl 
overexpression which has previously been associated 
with TKI resistance [22–27]. Therefore, AXL mRNA 
and Axl protein expression levels were assessed in the 
K562-R and K562 DOX-R cell lines. Figure 4A clearly 
demonstrates that AXL mRNA transcript level was 
significantly increased: a 6.3 fold increase in the K562-R 
line compared to the K562 control line (n=3, p<0.005); a 
1.5 fold increase in the K562 DOX-R line compared to the 
K562 DOX control line (n=3, p=0.03).
Next, the Axl protein level was assessed in the 
two resistant cell lines by flow cytometry. As indicated 
in Figure 4B, the cell surface expression of Axl in the 
K562-R and K562 DOX-R resistant cell lines was 
dramatically increased compared to their corresponding 
control lines. Taken together, these data confirmed the 
overexpression of Axl in the two Bcr-Abl-independent 
resistant cell lines.
Axl inhibition in the K562-R and K562 DOX-R 
ponatinib resistant lines restored sensitivity to 
ponatinib
Since Axl was overexpressed in the two resistant 
lines, we next determined if Axl inhibition might restore 
ponatinib sensitivity. A specific pharmacological Axl 
inhibitor, R428 was employed. R428 is 50 to 100-fold 
Figure 3: Resistant cell lines K562-R and K562 DOX-R demonstrate increased adhesion compared to their 
corresponding control lines. (A) Adherent cells were observed in both resistant cell lines, but not in their respective control lines, by 
light microscopy with 20X magnification. (B) Cells from resistant and control cultures were analysed by flow cytometry for expression of 
the adhesion marker CD44 (CD44-PE green; unstained grey; IgG2b PE isotype control red).
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more specific in targeting Axl than the other TAM family 
members (Mer and Tyro3) [34–37]. Additionally, MET-
branded inhibitor BMS-777607, which is 3 times more 
potent against Axl than MET, was also employed. Figure 
5A-5B demonstrated that in the presence of 1 μM R428 or 
12.5 μM BMS777607 (both concentration chosen based 
on previous publications) [38–40], and 200 nM ponatinib 
(the culture concentration of ponatinib), the viability 
of K562-R (n=3, p=0.02 and p=0.03 respectively) and 
K562 DOX-R (n=4, p=0.02 and p<0.01 respectively) 
resistant lines was significantly reduced compared to their 
corresponding control lines.
Taken together, these results indicate that Axl 
inhibition restored ponatinib sensitivity in the two Bcr-
Abl independent resistant cell lines, suggesting that Axl 
is critical in mediating Bcr-Abl independent ponatinib 
resistance in these cell lines.
AXL knock-down in the K562-R and K562 
DOX-R ponatinib resistant lines restored 
sensitivity to ponatinib
To further confirm that Axl plays a role in the Bcr-
Abl independent ponatinib resistance, AXL was knocked-
down in the K562-R, and K562 DOX-R resistant cell 
lines by Lentiviral shRNA (with a GFP tag). Stable AXL 
knock-down K562-R-AXL KD, and K562 DOX-R-AXL 
KD cell lines were generated, as well as the scramble 
control lines K562-R-scramble CTL, and K562 DOX-R-
scramble CTL. The positive expression of GFP in the AXL 
knock-down and scramble cell lines indicated the success 
of the transduction (Supplementary Figure 7A, 7B), which 
was further confirmed by the dramatic reductions in Axl 
expression in the knock-down cell lines (Figure 5C, 5D).
Next, the successfully transduced cell lines were 
exposed to ponatinib to determine whether AXL knock-
down reduced ponatinib resistance. As demonstrated 
in Figure 5E), the K562-R-AXL KD cell line exhibited 
a dramatic decrease (68% reduction) in viability after 
incubating with 10 nM ponatinib for 72 hours. This 
reduction was significantly higher (n=3, p=0.03) compared 
to the reduction in the control line treated with scrambled 
shRNA (22% reduction). In addition, the level of this 
reduction was similar to the K562 parental ponatinib naïve 
control (n=3), suggesting that AXL knock-down restores 
ponatinib sensitivity in the K562-R resistant cell line to 
the parental control level.
The AXL knock-down in the K562 DOX-R resistant 
cell line also demonstrated a significant decrease in 
viability (53% reduction) compared to the corresponding 
control line treated with scrambled shRNA (16% 
reduction) (n=3, p=0.02) (Figure 5F) after incubating with 
10 nM ponatinib for 72 hours. Again, the extent of cell 
death in the presence of 10 nM ponatinib following AXL 
knock-down was not significantly different to the K562 
DOX parental control (n=3). This result suggested that 
AXL knock-down is responsible for restoring ponatinib 
sensitivity in the K562 DOX-R resistant cell line, to a 
level that was comparable to that observed in the ponatinib 
naïve parental control.
DISCUSSION
In vitro cell line models have been used extensively 
to characterise resistance to the first and second generation 
TKIs in CML: our group and others have previously 
generated imatinib, nilotinib and dasatinib resistance in 
human and/or murine BCR-ABL1+ cell lines by culturing 
with gradually increasing concentrations of TKIs in a step-
wise manner [16, 19, 28, 29]. TKI resistance mechanisms 
generated by this method were found to be similar to those 
observed in the clinic [16, 19, 28, 29]. Hence the same 
method was employed in the current study to investigate 
ponatinib resistance.
Five BCR-ABL1+ cell lines were chosen as in 
vitro models for ponatinib resistance development, with 
resistance successfully generated in 4 of the 5 cell lines 
(Table 1). Variable ponatinib responses were observed 
in different cell lines but resistance to ponatinib was 
shared by all of the resistant cell lines despite the different 
resistant mechanisms. Of note, after three times attempted, 
ponatinib resistance was not achieved by using KU812 
cell line model. KU812 cells contained less copies of 
BCR-ABL1 compared to the K562 and K562 variants, 
hence it is much sensitive to ponatinib.
Ponatinib resistance was generated in two dasatinib 
pre-treated cell lines, K562 T315I and K562 DOX 55D, 
and Bcr-Abl dependent mechanisms were identified to 
confer resistance. The K562 T315I-R ponatinib resistant 
line demonstrated an increased in the percentage of the 
T315I mutation and an increase in BCR-ABL1 mRNA 
transcript level. The K562 DOX 55D-R resistant line 
also demonstrated Bcr-Abl dependent resistance, with the 
emergence of the compound mutations G250E/E255K. 
This result is in line with a previous study demonstrating 
that sequential ponatinib-inclusive TKI treatments could 
result in the development of compound mutations [7]; 
and while ponatinib efficiently targets all of the identified 
single KD mutations, some compound mutations can 
induce ponatinib resistance [7]. Interestingly, cases of 
G250E and E255K mutations appearing in imatinib or 
ponatinib treated patients were reported recently [41, 42], 
although, whether these two mutations were compounds 
was unclear. Hence, while the G250E/E255K compound 
mutations have not previously been reported, this study 
suggests that these compound mutations are likely to 
develop and confer resistance to ponatinib and other TKIs. 
Furthermore, a previous study showed that the P-loop 
mutation E255K in Bcr-Abl was close to the binding 
site of ponatinib and could affect the ponatinib efficacy. 
However, another P-loop mutation by itself, G250E, 
did not directly affect ponatinib binding [43]. While the 
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structural interaction of ponatinib with Bcr-Abl harbouring 
both of these mutations remains unclear, the insensitivity 
of the K562 DOX 55D-R cell line to ponatinib confirms 
that an E255K/G250E compound mutations result in 
ponatinib resistance in vitro.
The K562-R and K562 DOX-R cell line models 
indicate that increased survival signalling through 
alternative kinase driven pathways, regardless of Bcr-
Abl activity, play a role in the development of ponatinib 
resistance in the TKI naïve setting, as evidenced by the 
activation of Axl in this study. Previous publication 
indicates that AXL mRNA overexpression has been 
associated with imatinib and nilotinib resistant CML 
and therefore this gene alteration could be a potential 
biomarker to predict TKI treatment failure [22]. Here, 
both AXL mRNA and Axl protein overexpression was 
observed in the resistant cell lines. With Axl inhibition 
via small molecule inhibitors, ponatinib effectively 
induced apoptosis in the cell lines. In addition, the knock-
down of AXL completely restored ponatinib sensitivity. 
These results indicated that Axl overexpression is critical 
in mediating survival and resistance. Of note, AXL 
knock-down is more effectively induced ponatinib cell 
death compared to the use of inhibitors. This may be due 
to shRNA is more specific in targeting Axl compared to 
the Axl inhibitors. This finding is in line with a recent 
publication that suggested that inhibition of Axl re-
sensitised the ponatinib resistant cell lines and patient 
cells [44].
Axl inhibition re-sensitised the two resistant cell 
lines to ponatinib suggesting that combination therapy 
may be warranted in the Bcr-Abl independent ponatinib 
resistant setting. As the ATP-competitive Axl inhibitor 
R428 is already in Phase I clinical trial in acute myeloid 
leukaemia and Phase II trial in lung cancer, this provides 
a pathway for clinical studies in CML. Moreover, 
measurement of Axl expression level by flow cyotometry 
could potentially be used to risk-stratify patients who 
receive ponatinib therapy.
In conclusion, the work presented here demonstrates 
that ponatinib resistance can be generated in vitro and is 
therefore likely to be clinically relevant, as it is for all the 
first and second generation TKIs. This is the first study 
to present evidence that an increased proportion of T315I 
decreases sensitivity to ponatinib, and the emergence of 
compound mutations G250E/E255K result in ponatinib 
resistance. More importantly, in the context of recent 
clinical studies where ponatinib has been used in the 
early stages of CML therapy, Axl overexpression was 
identified to confer Bcr-Abl independent resistance in the 
TKI-naïve setting. Accordingly, inhibition of Axl reverses 
resistance to ponatinib. From a clinical perspective, 
examination of Axl expression level in patient leukaemic 
cells may provide a predictor for their likely response 
Figure 4: K562-R and K562 DOX-R cell lines demonstrated increased expression of the pro-adhesion protein Axl. (A) 
AXL mRNA transcript was measured by RQ-PCR and the results were graphed as fold change compared to control lines. GUSB was used 
as control gene. Error bars represent SD. n=3 for all data. *p<0.05 and ***p<0.005. (B) Flow cytometric analysis for AXL (anti-AXL-PE) 
was performed on resistant cell lines K562-R and K562 DOX-R and the respective control cell lines K562 and K562 DOX (unstained pink; 
IgG1 PE isotype control green; Axl PE antibody blue).
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Figure 5: Inhibition of Axl restores ponatinib sensitivity in the K562-R and K562 DOX-R cell lines while AXL 
knockdown increases ponatinib sensitivity. (A, B) Viability as assessed by Flow cytometry (AnnexinV-PE/7AAD double negative). 
The presence of the Axl inhibitor R428 (1 μM) or BMS777607 (12.5 μM) induced cell death significantly in (A) K562-R and (B) K562 
DOX-R when co-treated with 200 nM ponatinib compared to their corresponding control lines. (C, D) Cell surface Axl expression was 
measured by flow cytometry in the AXL or scramble control shRNA transduced resistant cell lines. Compared to scramble control, AXL 
shRNA transduced cells demonstrated a reduction in Axl expression on the cell surface. (E, F) AXL knockdown in the K562 and K562 
DOX ponatinib resistant cell lines demonstrated re-sensitisation to 10 nM ponatinib. Error bars represent SD, n≥3. *p<0.05 and **p<0.01.
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to ponatinib therapy. Furthermore, determination of Axl 
protein expression level in patients insensitive to ponatinib 
therapy could be useful in designing rational combination 
therapeutic interventions for these patients.
MATERIALS AND METHODS
Cell lines
The human BCR-ABL1 negative cell line HEK 293T 
and HL60, and BCR-ABL1 positive cell lines K562 and 
KU812 were purchased from The American Type Tissue 
Culture Collection (Manassas, USA). The ABCB1-
overexpressing K562 variant, K562 DOX, was kindly 
provided by Prof. Leonie Ashman [45]. Two dasatinib 
resistant cell lines previously generated by Tang et al. 
[28] were used in this study: K562 T315I (named K562 
200nM DAS in the original paper) and K562 DOX 55D 
which had prior exposure to 200 nM and 55 nM dasatinib 
respectively (Supplementary Figure 1). The T315I 
mutation was present in the K562 T315I cell line while 
no mutation was detected in the K562 DOX 55D cell line.
To generate ponatinib resistance, all BCR-ABL1+ 
cell lines (Table 1 and Supplementary Figure 1) were 
cultured with increasing concentrations of ponatinib using 
methods previously described [16, 28]. Parental, serially 
passaged ponatinib-naïve K562, K562-DOX, K562-DOX 
55D and K562 T315I cell lines and 0.1% Di-methyl 
Sulfoxide (DMSO; Merck, Darmstadt, Germany) vehicle 
controls were maintained in parallel.
IC50 analysis
IC50 experiments for imatinib, nilotinib, dasatinib 
and ponatinib were determined by measuring the 
inhibition of the Bcr-Abl substrate CrkL by using the 
method as outlined by White et al. [46]. In brief, 2 x 105 
cells were incubated in the presence of TKI at 37oC (5% 
CO2) for 2 hours. After incubation, cells were washed and 
lysed in Laemmli buffer [27]. Proteins were resolved using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). Western blots were performed by using 
anti-CrkL antibody C20 (Santa Cruz Biotechnology). The 
percentage of p-CrkL to total CrkL was determined, and 
the concentration of TKI required to reduce pCrkL by 50% 
was recorded as the IC50 value.
Tyrosine kinase inhibitors and Axl inhibitors
Ponatinib (Selleckchem, Houston, USA), dasatinib 
(Symansis, Shanghai, China) and nilotinib (Symansis) 
were dissolved in DMSO (10mM). Imatinib (Symansis) 
was dissolved in water (10mM). Serial dilutions of all 
drugs were made immediately prior to use.
Axl inhibitors R428 and BMS-777607 (both from 
Selleckchem, Houston, USA) were dissolved in DMSO at 
10 mM. Serial dilutions were made in DMSO immediately 
prior to use.
BCR-ABL1 mRNA quantification and BCR-ABL1 
kinase domain sequencing
BCR-ABL1 quantification was performed as 
previously described [28, 47]. In brief, RNA was extracted 
from cells stored in Trizol solution (Invitrogen Australia, 
Australia). cDNA was synthesized using Superscript II 
(Invitrogen) and was used as a template in a quantitative 
PCR (RQ-PCR) reaction using the ABI Prism 7500 
sequencing detection system (Applied Biosystems, 
Australia). BCR-ABL1 transcript numbers were reported 
as BCR-ABL1/BCR%.
Sanger sequencing was performed as previously 
described [31, 47]. Briefly, RNA was extracted from 2 x 
106 cells, and cDNA synthesized as a template to amplify 
the KD of BCR-ABL in a long PCR reaction using the 
Expand Long Template PCR System (Roche, Australia). 
Products were purified using ExoSAP-IT (GE Healthcare, 
Sweden) and sent to Molecular Pathology (SA Pathology) 
for analysis.
Next generation sequencing (NGS) termed Single 
Molecule Consensus Sequencing (SMCS) was performed 
using previous method and kindly processed by Dr. Wendy 
Parker [32].
Immunophenotyping by Flow Cytometry: 
measurement of protein cell surface expression
5 × 105 cells were incubated with Hanks Balanced 
Salt Solution (HBSS) (JRH Biosciences, Australia) 
supplemented with 10mM Hepes (Sigma-Aldrich) and 
with corresponding isotype controls: IgG2aPE/IgG2bPE 
(Dako, Australia), IgG1PE (BD Biosciences, Australia); 
or PE-conjugated anti-hBCRP1 (ABCG2-PE) (R&D 
Systems, Australia), PE-conjugated anti-CD243 (ABCB1-
PE) (Beckman Coulter, Australia), PE-conjugated 
anti-hAxl (R&D Systems, Australia) or PE-conjugated 
anti-hCD44 (BD Biosciences, Australia) antibodies for 
40 minutes on ice. Following HBSS wash, cells were 
resuspended in fixative and analyzed by flow cytometry 
(BD LSRFortessa X20 Analyser, Australia). Results 
were analyzed by FCS Express 4 Research Flow Edition 
software (De Novo, US).
AXL transcript quantitation
AXL transcript levels were measured by RQ-PCR. 
GUSB was used as control gene and the expression level 
of AXL was calculated as a ratio of GUSB transcript levels. 
The primers used for AXL amplification were as follows:
AXL Forward primer: 5’ TGC ATG AAG GAA TTT 
GAC CA 3’
AXL Reverse primer: 5’ TCG TTC AGA ACC CTG 
GAA AC 3’
Samples were amplified in triplicate in the Rotor-
Gene 3000 PCR cycler machine (Corbett Research, 
Cambridgeshire, UK) with the following conditions: 
Oncotarget34745www.oncotarget.com
50°C for 2 min, 95°C for 10 min, 45 cycles of 95°C for 15 
seconds and 60°C for 1 min.
Viability assay
Cells were removed from drug-containing culture 
medium, washed and re-cultured in fresh media (with 
testing drug) for 72 hours. Cells then were stained with 
7-Amino-actinomycin D (7AAD) and Annexin V-PE. 
Flow cytometry (BD LSRFortessaTM X-20 with high-
throughput platform) was performed to determine 
cell viability: cells stained positive for Annexin V-PE 
and 7AAD were considered to be apoptotic or dead 
respectively. The data were analysed using FCS Express 
software (DeNovo Software, Los Angeles, California, 
USA).
Lentiviral transfection and transduction
HEK 293T cells were transfected by lentiviral 
shRNA plasmid pGFP-C-shLenti comprised of either 
scramble control vector (sequence as below) or AXL 
knock-down (sequence as below) with Green Fluorescense 
Protein (GFP; Origene, MD, USA) according to the 
manufacturer’s instructions. The GFP level and Axl 
expression level were measured after fluorescence-
activated cell sorting (FACS) and before each experiment 
to ensure purity.
Scramble control sequence:
5’ GCA CTA CCA GAG CTA ACT CAG ATA GTA 
CT 3’
AXL shRNA sequences:
5’ GAA CAG GAT GAC TGG ATA GTG GTC AGC 
CA 3’
Statistics
Comparison between two groups was performed 
using unpaired 2-tailed Student’s t-test or Kruskal-Wallis 
analysis of variance to determine statistical differences. 
Correlation between 2 groups was compared using Pearson’s 
correlation statistical analysis. The analysis was performed 
using GraphPad Prism 5 (GraphPad Software, La Jolla, CA). 
Statistically significant differences were defined as p<0.05.
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